Cortellini et al. retrospectively reviewed the impact of muscle quality on PFS in association with PD‐1/PD‐L1 inhibitor use in a mixed cancer population comprising 46 patients with advanced NSCLC and 54 patients with other advanced cancers including renal cell carcinoma and melanoma.14 Here, CD274 is linked to hereditary clear cell renal cell carcinoma.